At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
How you can devise a cancer prevention action plan.
How to love yourself — and your selfies — without filters or fillers.
Medication Treatment Study for snOH in Subjects with Primary Autonomic Failure
Clinical Trial Title:
Phase 3 clinical effect of TD-9855 for treating snOH in subjects with primary autonomic failure.
Clinical Trial Protocol ID:
18051001
Clinical Trial Investigator Name:
Katie Kompoliti, MD
Clinical Trial Protocol Description:
The SEQUOIA Study is a research study looking at a study drug for people with conditions such as Parkinson’s disease (PD) or multiple system atrophy (MSA) who have a drop in blood pressure upon standing. We want to learn how safe the study drug is and whether it can reduce these symptoms. Participation will last about 9 weeks, with 7 study visits.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have been diagnosed with Parkinson’s disease (PD) or multiple system atrophy (MSA),
- Have symptoms such as dizziness, light-headedness, feeling faint, or feeling like you might black out upon standing.
- Are 30 years of age or older.
- Meet additional eligibility criteria.
This is a partial list of inclusion and exclusion criteria.
Clinical Trial Area:
Parkinson's Disease and Other Movement Disorders
Contact Phone:
(312) 563-2900 (Press 4/Code: Sequoia 0169)
Contact Name:
Samantha Ruehl